SMN2 and spinal muscular atrophy, type III: To investigate whether NCDN requires the SMN protein for its localisation to vesicles in neural cells, SH-SY5Y cells were transfected with shRNA constructs previously validated to reduce the expression of SMN by an average of 46%, a reduction previously found to cause symptoms resembling SMA type III in mouse models (Jablonka et al., 2000), and carrying a GFP marker to unequivocally identify transfected cells (Clelland et al., 2012).